following a full submission:
aprepitant (Emend) is accepted for restricted use within NHS Scotland for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based chemotherapy.
The antiemetic regimen incorporating aprepitant was superior to one regimen (where dexamethasone alone was used in the delayed phase of treatment), for the prevention of cisplatin-induced nausea and vomiting in the acute and delayed phases. It should be initiated only by appropriate hospital based specialists.
Download detailed advice26KB (PDF)
Medicine details
- Medicine name:
- aprepitant (Emend)
- SMC ID:
- 132/04
- Indication:
- Prevention of acute and delayed nausea and vomiting associated with chemotherapy
- Pharmaceutical company
- MSD
- BNF chapter
- Central nervous system
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 08 November 2004
The marketing authorisation for aprepitant was extended to cover prevention of nausea and vomiting associated with highly emetogenic non-cisplatin based chemotherapy in January 2016. This minor licence change will not be assessed.